Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC (AZN) generates a steady flow of news driven by its global biopharmaceutical activities in Oncology, Rare Diseases and BioPharmaceuticals. Company announcements frequently cover clinical trial milestones, regulatory decisions, manufacturing investments and strategic collaborations, offering investors and healthcare professionals insight into how its pipeline and marketed medicines are evolving.
Recent news highlights include multiple updates on Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), two antibody drug conjugates jointly developed with Daiichi Sankyo. These stories describe new Phase 3 trials, Breakthrough Therapy Designations, and approvals in indications such as HER2-positive early breast cancer, metastatic breast cancer, HER2-expressing endometrial cancer and HER2-expressing ovarian cancer, as well as TROP2-directed approaches in lung and breast cancer.
News items also cover immuno-oncology developments with Imfinzi (durvalumab), including perioperative regimens for gastric and gastroesophageal junction cancers based on the MATTERHORN trial, and broader use in gastrointestinal and thoracic malignancies. In Rare Diseases and immunology, AstraZeneca reports on approvals for Koselugo in adult NF1-associated plexiform neurofibromas and on expanded administration options for Saphnelo in systemic lupus erythematosus.
Beyond clinical and regulatory updates, AstraZeneca’s news feed includes information on large-scale manufacturing investments in the United States, such as expansion of biologics facilities in Maryland, and technology partnerships like the selection of Salesforce’s Agentforce Life Sciences platform for AI-powered customer engagement. Visitors to this AZN news page can review these developments to understand how AstraZeneca’s pipeline, approvals and infrastructure may influence its long-term strategic direction.
AstraZeneca (NYSE:AZN) reported that the POTOMAC Phase III trial met its primary endpoint: adding one year of IMFINZI (durvalumab) to BCG induction and maintenance reduced the risk of high-risk non-muscle-invasive bladder cancer recurrence or death by 32% (DFS HR 0.68; 95% CI 0.50-0.93; P=0.0154) with median follow-up of 60.7 months. Estimated 24-month DFS rates were 86.5% (IMFINZI+BCG) vs 81.6% (BCG). OS was not formally powered; descriptive OS HR was 0.80 (95% CI 0.53-1.20) at 65.6 months. Grade 3‑4 adverse events occurred in 34% (IMFINZI arm) vs 17% (BCG). Results presented at ESMO 2025 and published in The Lancet.
AstraZeneca (NYSE:AZN) announced results from the MATTERHORN Phase III trial showing a perioperative IMFINZI (durvalumab) plus FLOT regimen reduced the risk of death by 22% versus chemotherapy alone (HR 0.78; 95% CI 0.63-0.96; P=0.021) in resectable Stage II–IVA gastric and gastroesophageal junction cancer. Median OS was not reached in either arm at data cut-off Sept 1, 2025. Estimated 3-year OS was 69% with IMFINZI-FLOT versus 62% with FLOT alone. Prior EFS analysis showed a 29% reduction in risk (HR 0.71; P<0.001).
AstraZeneca (NYSE:AZN) unveiled an expanded manufacturing facility in Coppell, Texas on October 15, 2025, backed by a $445 million investment to double Lokelma production for the US and global markets.
The expansion adds a 9,000 sq ft building, two novel manufacturing lines, upgraded labs, warehousing, utilities and administrative space. Coppell is the sole global Lokelma manufacturing site serving >50 countries and employs >250 people.
This project follows a recent groundbreaking in Virginia and is part of AstraZeneca’s announced $50 billion US R&D and manufacturing commitment over five years; the company reported creating approximately $20 billion of value to the US economy in 2025.
AstraZeneca (AZN) will present new clinical data at ESMO Congress, Oct 17–21, 2025, featuring first readouts from four major pivotal trials and more than 95 abstracts across approved and pipeline medicines.
Key highlights include Presidential Symposium presentations of DESTINY-Breast11 and DESTINY-Breast05 on ENHERTU in HER2-positive early breast cancer, primary results from TROPION-Breast02 on DATROWAY in metastatic TNBC, and POTOMAC and MATTERHORN results for IMFINZI in early bladder and gastric cancers. The program also features 26 oral presentations and data on multiple ADCs, IO bispecifics and combination regimens.
AstraZeneca (AZN) will increase investment in a new Virginia manufacturing facility to $4.5 billion, a $500m boost to expand capability to produce a broader range of medicines including weight‑management small molecules and antibody drug conjugate (ADC) cancer therapies.
The Rivanna Futures site in Albemarle County is expected to create approximately 3,600 jobs (about 600 ongoing skilled roles and 3,000 construction roles). Work starts immediately and the facility is expected to be operational in 4–5 years. The project is part of a $50 billion U.S. R&D and manufacturing commitment and will deploy AI, automation, and data analytics.
Turbine announced a collaboration with AstraZeneca (AZN) on October 9, 2025 to apply Turbine's virtual disease models to antibody-drug conjugate (ADC) discovery.
The partnership will use a lab-in-the-loop workflow where Turbine recommends a strategic subset of cell lines for wet-lab testing, then predicts outcomes across thousands of in silico models using AstraZeneca's ADC datasets, covering single-agent and combination studies. Goals include reducing large-scale cell line screening, improving speed and efficiency of ADC discovery, and delivering mechanistic insights by modeling cell survival and gene-expression changes to inform ADC positioning and clinical translatability.
AstraZeneca (NYSE:AZN) announced that baxdrostat met the primary endpoint in the Phase III Bax24 trial, showing a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure versus placebo at Week 12 in patients with resistant hypertension.
The randomized, double-blind study randomized 218 participants 1:1 to baxdrostat 2 mg or placebo for a 12-week double-blind period. Efficacy was observed across the full 24-hour period, including the high-risk early morning window. Baxdrostat was generally well tolerated with a safety profile consistent with prior BaxHTN results. Data will be shared with regulators and presented at AHA Scientific Sessions November 2025.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced positive Phase III TROPION-Breast02 results for DATROWAY (datopotamab deruxtecan-dlnk) on October 6, 2025.
DATROWAY showed a statistically significant, clinically meaningful improvement in overall survival (OS) and a highly statistically significant improvement in progression-free survival (PFS) versus investigator's choice chemotherapy as 1st-line treatment for metastatic triple-negative breast cancer (TNBC) patients for whom immunotherapy was not an option. Approximately 70% of metastatic TNBC patients are not candidates for immunotherapy.
The safety profile was consistent with prior trials; common adverse reactions included stomatitis (63%), ocular reactions (36%), and ILD/pneumonitis observed in the pooled breast-cancer population at 3.6% (one fatal case, 0.2%). Data will be presented at a medical meeting and shared with regulators.
AstraZeneca (AZN) and Daiichi Sankyo reported positive topline results from the phase 3 TROPION-Breast02 trial: DATROWAY (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus investigator’s choice chemotherapy as first-line therapy for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option. The PR also states a highly statistically significant improvement in progression-free survival (PFS) (dual primary endpoints). The companies say plans for global regulatory submissions are underway and that the DATROWAY safety profile was consistent with prior trials. Data will be presented at an upcoming medical meeting and companies are running three additional phase 3 TNBC trials.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo announced that the FDA has accepted their supplemental Biologics License Application (sBLA) for ENHERTU® followed by THP for review in high-risk HER2-positive early-stage breast cancer patients prior to surgery.
The application is based on the DESTINY-Breast11 phase 3 trial, which demonstrated statistically significant improvements in pathologic complete response (pCR) rates compared to standard treatment. The trial also showed an improved safety profile and early positive trend in event-free survival. The FDA target action date is set for May 18, 2026.
This potential approval could represent a new treatment approach for patients with high-risk HER2-positive early-stage breast cancer, where currently nearly half of patients don't achieve pCR with existing neoadjuvant treatments.